Related Experiment Videos
When are placebo-controlled trials no longer appropriate?
1Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas 77030, USA.
Controlled Clinical Trials
|December 31, 1997
Summary
This study introduces an ethical standard for placebo-controlled trials, ensuring patient safety by categorizing acceptable risks for control groups. It demonstrates how to conduct essential research while upholding ethical guidelines, using thrombolytic agent trials as examples.
Area of Science:
- Clinical Trials
- Medical Ethics
- Cardiology
Background:
- Placebo-controlled trials are crucial for drug efficacy assessment.
- Ethical concerns arise when placebo groups may be denied effective treatments.
- Thrombolytic agent trials highlight these ethical dilemmas.
Purpose of the Study:
- To propose a standard for evaluating placebo-controlled trials ethically.
- To define acceptable risk levels for participants in control groups.
- To ensure ethical conduct of clinical research without compromising patient welfare.
Main Methods:
- Developed a risk categorization framework for research subjects.
- Applied the standard to analyze major thrombolytic agent trials.
- Illustrated ethical considerations in clinical trial design.
Main Results:
- A clear standard for assessing the ethical validity of placebo-controlled trials was established.
- The framework differentiates between permissible and impermissible risks for control groups.
- Demonstrated feasibility of conducting necessary research under the proposed ethical standard.
Conclusions:
- The proposed standard provides a robust ethical framework for placebo-controlled trials.
- It balances the need for rigorous scientific inquiry with the protection of research participants.
- Ethical trial design is achievable, even in complex therapeutic areas like cardiology.